Abstract Number: PB0143
Meeting: ISTH 2020 Congress
Background: Venous thromboembolism (VTE) refers to formation of blood clot in the veins. This include deep vein thrombosis (DVT), and pulmonary embolism (PE). Although recombinant atherogenic antigen (AHC) containing epitopes derived from ApoB, heat shock protein (HSP) 60, and Chlamydia pneumoniae outer membrane protein would represent the most successful vaccine candidate to reduce autoantigen (such as ApoB and HSP)-associated inflammation towards atherosclerosis, little is known about the effect of the immune response induced by AHC construct containing autoantigen epitopes on VTE.
Aims: To assess whether immunization of C57BL/6 mice with the recombinant atherosclerotic antigen AHC has an effect in a carrageenan-induced mouse tail thrombosis model.
Methods: 6-week old C57BL/6 mice (N=6-8 per group) were immunized with AHC and a non-immunized group of mice were used as controls. Two weeks after the first immunization, VTE was induced by injection of carrageenan into the tail vein of the mice. Blood samples were collected and the plasma was tested for cytokine levels by ELISA.
Results: Similar plasma levels of thrombosis markers (TCK-1, IL-6, IL-10, fibrinogen, and TIMP-1) were observed in AHC-immunized mice and non-immunized controls.
Conclusions: Immune response to AHC did not contribute to promotion of VTE in tested mice.
To cite this abstract in AMA style:Xia M, Endresz V, Lantos I, Szabo A, Lu X. Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Increase Susceptibility to Venous Thrombosis [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/immunization-with-recombinant-atherogenic-antigen-ahc-does-not-increase-susceptibility-to-venous-thrombosis/. Accessed May 6, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/immunization-with-recombinant-atherogenic-antigen-ahc-does-not-increase-susceptibility-to-venous-thrombosis/